Kornimate/medical-research-clean huggingface dataset:
long-term of remote ischemic preconditioning in patients with mild hypertension

Conditions: Hypertension

Summary: according to the latest survey data of china hypertension annual meeting, there are about 300 million patients with hypertension in china, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. in particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. at present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. for most patients with mild hypertension, drug control is not the best choice. it has been reported that remote ischemic preconditioning (ripc) may play an effective role in reducing blood pressure .the purpose of this study was to investigate the extent of long-term application of ripc to reduce blood pressure in patients with mild hypertension.

a total of 200 patients with mild hypertension were enrolled in this study, using the method of open label and parallel grouping; 100 cases in the experimental group and 100 cases in the control group, the experimental group was divided into life intervention + drug group and life intervention + ripc group, with 50 patients in each group. the results of 24-hour ambulatory blood pressure monitoring (abpm) of the three groups were observed before and 3 months after use, including hr, pulse pressure, 24-hour systolic blood pressure, 24-hour diastolic blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, nighttime systolic blood pressure and nighttime diastolic blood pressure. the changes of renalase, catecholamine, renin, angiotensin - ⅱ, aldosterone, rhoa kinase, no, adenosine and bradykinin were observed.

Eligibility criteria:
inclusion criteria: * diagnosed patients with mild hypertension (sbp: 140\~159mmhg; dbp: 90\~99mmhg) exclusion criteria: * cannot tolerate ripc * non-essential hypertension * patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance * patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
assessing efficacy and safety of dextenza 0.4 mg insert, following corneal transplant surgery

Conditions: Corneal Edema; Corneal Defect; Corneal Transplant; Penetrating KeratoPlasty; Anterior Chamber Inflammation; Ocular Pain; Intraocular Pressure

Summary: assessing the efficacy and safety of dextenza, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (pkp, dsek, dmek) as compared to topical prednisolone acetate 1%.

assessing the efficacy and safety of dextenza, sustained release dexamethasone 0.4 mg insert, when placed within the lower or upper eye lid canaliculus in conjunction with topical prednisolone acetate 1% for the treatment of pain, and inflammation following corneal transplant surgery (pkp, dsek, dmek) as compared to topical prednisolone acetate 1%.

Eligibility criteria:
inclusion criteria: a patient's study eye must meet the following criteria to be eligible for inclusion in the study: * age 18 years and older * scheduled corneal transplant surgery: pkp, dsek, dmek * willing and able to comply with clinic visits and study related procedures * willing and able to sign the informed consent form exclusion criteria: a patient who meets any of the following criteria will be excluded from the study: * patients under the age of 18. * pregnancy (must be ruled out in women of child-bearing age with pregnancy test) * active infectious systemic disease * active infectious ocular or extraocular disease * presence of punctal plug in the study eye * obstructed nasolacrimal duct in the study eye(s) * hypersensitivity to dexamethasone or prednisolone eye drops * patients being treated with immunomodulating agents in the study eye(s) * patients being treated with immunosuppressants and/or oral steroids * patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
an open-label study to enable continued treatment access for subjects previously enrolled in studies of ruxolitinib

Conditions: Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer; Lung Cancer

Summary: the purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. this study will also provide another mechanism for reporting adverse events related to study drug safety.


Eligibility criteria:
inclusion criteria: * currently enrolled and receiving treatment in an incyte-sponsored clinical study of ruxolitinib that has completed or been terminated. * currently tolerating treatment in the parent protocol. * currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator. * have at least stable disease, as determined by the investigator. * has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. exclusion criteria: * has been permanently discontinued from study treatment in the parent study for any reason. * able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Keywords: solid tumors ruxolitinib regorafenib capecitabine
metabolic factors of outcomes from gastric bypass surgery

Conditions: Obesity

Summary: the objective of this study is to determine whether the metabolic, endocrine and energetic response to short term caloric restriction are factors in weight loss in subjects having gastric bypass (gb) surgery.


Eligibility criteria:
inclusion criteria: subjects satisfying the following criteria will be considered the screening population and will be eligible for enrollment in this study: 1. subject is willing to give consent and comply with evaluation and treatment schedule 2. 18 to 65 years of age (inclusive) on date of signing the icd 3. subject is scheduled to have non-revisional gb surgery between 2 weeks to 4 months after signing the icd 4. able to read, understand, and follow study procedures as outlined in the icd. exclusion criteria: subjects meeting the following criteria will not be eligible for enrollment: 1. unable or unwilling to attend follow-up visits and examinations 2. women who are pregnant, nursing at the time of screening, or planning to become pregnant within one year of the gb surgery 3. clinically active cardiac, renal, hepatic or gi disorders 4. screening laboratory tests with any of the following: * alanine aminotransferase \[alt\] and/or aspartate aminotransferase \[ast\] ≥ 4 times upper limit of normal (uln) according to vamc normal ranges * ast:alt \> 2:1 according to vamc normal ranges * serum creatinine ≥ 1.5 times uln according to vamc normal ranges * blood urea nitrogen (bun) ≥ 1.5 times uln according to vamc normal ranges * positive test results for hepatitis a, b or c 5. clinically active thyroid or lipid disorders: * thyroid-stimulating hormone (tsh) flagged as critical value (per vamc lab normal ranges) * triglycerides \> 400 mg/dl 6. anemia: * mean corpuscular volume (mcv), mean corpuscular hemoglobin (mch), and mean corpuscular hemoglobin concentration (mchc) outside normal vamc range; or * hematocrit \< 36% 7. uncontrolled hypertension which required a medication regimen adjustment during the 3 months prior to screening 8. currently prescribed or taking atypical antipsychotic medication 9. currently prescribed or taking chronic, long-term, oral corticosteroid medication 10. diabetes requiring a drug regimen which includes insulin treatment at the time of screening 11. unwilling or unable to refrain from having a procedure or surgery which involves the removal of skin tissue which could result in weight loss 12. any medical condition or finding for which the pi used medical discretion to determine the subject should be excluded; or 13. participation in any other investigational device or drug study (non survey based trial) during the course of the trial.

Keywords: obesity gastric bypass roux en y
total neoadjuvant treatment of rectal cancer by mri-guided radiotherapy

Conditions: Rectal Cancer

Summary: the tntrect trial is a prospective observational study that will evaluate the outcome of mr-guided stereotactic body radiotherapy (sbrt) with a simultaneous integrated boost in a hypofractionated treatment of rectum cancer. patients will be treated in 5 daily fractions of 5 gy within an overall treatment time (ott) of 5 days. a simultaneous integrated boost (sib) till 30gy will be delivered to the gross tumor volume. patients will be treated with daily adaptive radiotherapy and online tumor gating on the mridian system (viewray inc.). the aim of the study is to improve the complete clinical response rate to offer more patients an organ preserving approach. the primary endpoint is patient response to the treatment, assessed by endoscopy and mri, or by medical pathology reports after potential resection was performed. as secondary endpoints local control, disease-free survival, overall survival and the patient's quality of life \& hospital anxiety and depression will be measured.


Eligibility criteria:
inclusion criteria: * locally advanced rectal cancer exclusion criteria: * patients with unresectable metastatic disease at diagnosis * patients with an ecog performance status \> 2 * patients not deemed fit for radiotherapy, chemotherapy or surgery

Keywords: radiation therapy mr-guided radiotherapy stereotactic body radiotherapy total neo-adjuvant treatment
cure rates of superficial basal cell carcinoma (bcc) edc

Conditions: Superficial Basal Cell Carcinoma

Summary: this is a prospective, randomized clinical trial conducted at the unviersity of wisconsin (uw) dermatology clinic located at 1 s. park street, madison, wi 53715. there are no controls. subjects meeting eligibility criteria are randomly divided into one of two treatment groups (ed\&c x 1 cycle or ed\&c x 3 cycles) using computer generated random numbers. one cycle of ed\&c is defined according to standard technique currently employed. it involves scraping away the tumor with a curette (ring- shaped instrument) and then burning the curetted site with a small electric needle (electrodessication). during visit 1, the surgical site is marked, local numbing medication is injected, and 1 or 3 cycles of ed\&c is/are performed by board-certified dermatologists or a dermatology resident under the direct supervision of a board certified dermatologist. all follow-up visits (3, 6, 9, and 12 months after visit 1) include skin evaluations by the physician who performed the ed\&c. the lesion site is examined, measured, and photographed for clinical evidence of recurrence, as defined by a new lesion within the previously treated site. if there is evidence of possible tumor recurrence at the treated surgical site during visit 2, 3, 4 or 5, then the lesion will be biopsied using a shave procedure.


Eligibility criteria:
inclusion criteria: * untreated, biopsy proven superficial type basal cell carcinoma (bcc-s) on the trunk and/or extremities * age greater than 21 * women with childbearing potential (including those who are pregnant/lactating) * able to provide written informed consent exclusion criteria: * aggressive histology on initial biopsy (i.e. morpheaform, infiltrative, desmoplastic, or purely micronodular) * prior history of bcc or other skin cancer at the same location * lesion \> 2 cm * patients with basal cell nevus syndrome * transplant patients * immunocompromised patients * recurrent bcc * greater than 2 bcc-s on the trunk and/or extremities * prisoners * allergy to lidocaine or epinephrine
efficacy and safety of xen63 gel implant

Conditions: Glaucoma

Summary: the study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the xen63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for iop not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing iop values before and 24 months after implantation.

the study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the xen63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for iop not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing iop values before and 24 months after implantation. every patients will be followed for 24 months. secondary aims of the study are: * evaluating the hypotensive efficacy of the xen63 12 months after implantation. * assessing the safety of the xen63 device after 12 and 24 months after implantation. * comparing the hypotensive efficacy of the xen63 in glaucomatous patients undergoing the solo procedure and in those undergoing the combo procedure * evaluating the quality of life of patients undergoing xen63 implantation 12 and 24 months after implantation. * evaluating the association between factors related to the patient, the surgical technique or post-operative management and the hypotensive efficacy of the device during follow-up.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the european glaucoma society guidelines. 3. need for xen63 implantation for iop not controlled by medical therapy, progression of disease or intolerance to topical therapy, in association or not with cataract surgery. 4. informed consent freely given and obtained before the start of the study. 5. the participant has the ability to understand and the willingness to follow the study instructions and is likely to complete all required visits and procedures. exclusion criteria: 1. closed-angle glaucoma 2. previous trabeculectomy or valve or tube placement. 3. presence of conjunctival scarring, previous conjunctival surgery or other conjunctival pathologies (e.g. pterygium) in the target quadrant. 4. signs of active inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis) 5. active iris neovascularization or presence of iris new vessels within 6 months of the date of surgery 6. anterior chamber lenses 7. presence of intraocular silicone oil 8. vitreous in anterior chamber 9. altered episcleral venous drainage (e.g. sturge webwer syndrome, nanophthalmos) 10. known or suspected allergy or sensitization to medications required for the surgical procedure or some component of the device (e.g. glutaraldehyde or porcine derivatives) 11. history of predisposition to the formation of keloids. 12. pregnancy or breastfeeding.

Keywords: glaucoma surgery xen63
a study to investigate efficacy and safety of vtama (tapinarof) cream, 1% in intertriginous plaque psoriasis

Conditions: Psoriasis

Summary: this is an open-label, multi-center study to evaluate the efficacy and safety of vtama (tapinarof) cream, 1% in adults with intertriginous psoriasis

this is an open-label study in which participants will be assigned to receive vtama (tapinarof) cream, 1% once daily for 12 weeks. study participants will have a follow-up period of 1 week. the study duration will be up to 17 weeks.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, at the time of signing the informed consent * participants with clinical diagnosis of plaque psoriasis, including lesion(s) in intertriginous area(s) and stable disease in intertriginous areas for at least 3 months prior to the study * an ipga score of 2 (mild), 3 (moderate), or 4 (severe) at screening and baseline * female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study * negative pregnancy test at baseline (day 1) * capable of giving written informed consent exclusion criteria: * diagnosis of a type of psoriasis other than plaque psoriasis * any sign of infection of any of the psoriatic lesions * concurrent significant dermatologic or inflammatory condition other than plaque psoriasis that, in the investigator's opinion, would make it difficult to interpret data or assessments during the study * history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, may interfere with participation in the study and ability to understand and give informed consent * history of sensitivity to the study product, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study * previous known participation in a clinical study with tapinarof (previously known as gsk2894512 and wbi-1001); previous or current use of vtama® (tapinarof) cream 1% * use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) * uv light therapy or prolonged exposure to natural or artificial sources of uv radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the baseline

Keywords: tapinarof plaque psoriasis adult phase 4 topical open-label efficacy safety psoriasis intertriginous psoriasis inverse psoriasis
vegf and pedf in patients with myopic choroidal neovascularization

Conditions: Myopic Choroidal Neovascularization; VEGF Aqueous Level; PEDF Aqueous Level

Summary: this was a prospective, case-control study investigating aqueous levels of vegf and pedf in eyes with mcnv treated with ivb.


Eligibility criteria:
inclusion criteria: * pathologic myopia, defined as spherical equivalent \>6 diopters and axial length \>26 mm * posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent); * fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization * clear ocular media; exclusion criteria: * previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or pdt * presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion * history of recent myocardial infarction or other thromboembolic events * ongoing uncontrolled hypertension or glaucoma * refractive media opacities * previous eye surgery
study of infections in patients with autoimmune diseases treated with rituximab

Conditions: Autoimmune Diseases

Summary: rituximab is a very effective drug used to treat many inflammatory diseases. these diseases include, for example, rheumatoid arthritis, multiple sclerosis and systemic autoimmune diseases. the major drawback of this drug is the risk of infection, which are favored by the direct effect of rituximab on the immune system. the risk of infection is one of the major reason not to prescribe or withdraw rituximab in several patients. however, many questions remain unanswered regarding the proportion and risk factors of infection or immunodeficiency induced by rituximab. better understanding of these issues will help prescribing rituximab and properly monitor patients during their treatment. moreover, as treatment with substitutive immunoglobulins might be a solution to decrease the risk of infections in those patients, it is very important to better characterize the risk and risk factors of rituximab-associated infection. the present study aims to answer these questions.


Eligibility criteria:
inclusion criteria: * patient initiating treatment with rtx, delivered by the central pharmacy of lille university hospital * inpatient or outpatient at lille university hospital (in one of the following departments: internal medicine, rheumatology, neurology, dermatology, pneumology) and monitored every three months as part of routine care (as part of the surveillance of induction of rtx treatment) * patient with one of the following autoimmune diseases, defined by international criteria exclusion criteria: * treatment with rituximab for a malignancy or a transplant reject * pregnant or lactating women * people in emergency * administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system, refusal to sign consent * persons deprived of their liberty * people unable to consent

Keywords: infections immunoglobulins secondary immunodeficiency rituximab
validity and reliability of iphone application in internal rotation measurement

Conditions: Shoulder Pain

Summary: the validity and reliability of active internal rotation rom measurement of shoulder with smartphone in patients with shoulder pain was investigated.

eighteen patients with shoulder pain who applied to the physical medicine and rehabilitation, shoulder subspecialty outpatient clinic who agreed to participate in the study and 18 volunteers who had not experienced shoulder pain before enrolled in the study. participant age range was determined as 40-70 years. the ihandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. in this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iphone application. the participants were asked to lie on the bed in supine position with shoulder to be measured at the edge of the bed. the measured shoulder was positioned at 90 degrees abduction, 90 degrees elbow flexion and forearm at neutral position. the participant was asked to bring the wrist closer to the bed in the direction of the little finger, and was measured at the angle that the shoulder could not move without lifting the arm. in the measurement made with the application, the phone was held parallel to the ulna and the value displayed on the screen was recorded. the participant were asked to repeat the movement if his/her shoulder lift up of bed, straightened his/her elbow, or did anything that would disrupt her movement pattern. each measurement was repeated 3 times and after 2 weeks the control measurements were made by repeating 3 times. measurements were conducted separately in different cabinets without seeing each other for each participant by 1 physical medicine and rehabilitation specialist and 1 physiotherapist. the measurements were recorded in separate locations until all participants were completed.

Eligibility criteria:
inclusion criteria: * patient with shoulder pain * 40-70 years old * agreed to participate the study exclusion criteria: * \ 70 years old * not agreed to participate